MCO Molecular and Clinical Oncology 2049-9450 2049-9469 D.A. Spandidos 10.3892/mco.2017.1360 MCO-0-0-1360 Articles T-cell immunoglobulin mucin-3 expression in invasive ductal breast carcinoma: Clinicopathological correlations and association with tumor infiltration by cytotoxic lymphocytes ZhangHuan 1 XiangRong 2 WuBin 3 LiJinlong 1 LuoGuilin 1 Department of General Surgery, The Fourth People's Hospital of Sichuan, Chengdu, Sichuan 610000, P.R. China Department of Medicine, Nan Kai University, Tianjin 300071, P.R. China Department of Breast Surgery, Southwest Medical University Affiliated Hospital, Luzhou, Sichuan 646000, P.R. China Correspondence to: Dr Jinglong Li, Department of General Surgery, The Fourth People's Hospital of Sichuan, East 57th Street, Jinjiang, Chengdu, Sichuan 610000, P.R. China, E-mail: 825895181@qq.com 10 2017 03 08 2017 7 4 557 563 16092016 08032017 Copyright: © Zhang et al. 2017 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

As a negative regulatory molecule, T-cell immunoglobulin and mucin domain-3 (Tim-3) is closely associated with tumor immunological tolerance. The aim of this study was to investigate Tim-3 expression in invasive ductal breast cancer (IDC), its effect on clinicopathological parameters and its association with cytotoxic lymphocyte infiltration. Tim-3 protein expression was measured in 150 paraffin-embedded IDC specimens and 100 paired normal breast tissue specimens by immunohistochemistry. It was demonstrated that the infiltration of the tumor by CD8+ T cells was significantly higher compared with that of normal tissue, and the Tim-3 expression on CD8+ T cells was higher in IDC tissue compared with that in normal tissue; the differences were statistically significant (both P-values=0.000). The median expression level of Tim-3 on tumor cells was significantly associated with clinicopathological parameters such as age, axillary lymph node metastasis and TNM stage (P=0.015, 0.001 and 0.027, respectively). The expression of Tim-3 on CD8+ T cells was correlated with lymph node metastasis, World Health Organization (WHO) grade and molecular classification (P=0.000, 0.004 and 0.000, respectively). Additionally, the number of tumor-infiltrating CD8+ T cells was associated with primary tumor size, lymph node metastasis, WHO grade, Ki-67 and molecular classification (P=0.017, 0.002, 0.007, 0.003 and 0.000, respectively). Thus, Tim-3 may promote the development and progression of breast cancer and affect the tumor microenvironment; thus, it may be used as an independent prognostic factor for IDC patients.

 invasive ductal breast cancer T-cell immunoglobulin and mucin domain-3 tumor-infiltrating cytotoxic lymphocyte immune regulation tumor invasion and metastasis immunohistochemical Introduction

Breast cancer is a major health concern worldwide and the most common type of cancer among women (1), with a reported 458,000 deaths annually, making it the most common cause of cancer-related mortality among women in developed as well as developing countries (2). Therefore, there is an urgent need for novel biomarkers for the prognosis and effective treatment of breast cancer. The T-cell immunoglobulin and mucin domain (TIM) gene family was positionally cloned in 2001 from within the T-cell and airway phenotype regulator locus as novel allergy and asthma susceptibility genes (3). The TIM gene family consists of eight members (TIM-1-8) on mouse chromosome 11B1.1, and three members (TIM-1, TIM-3 and TIM-4) on human chromosome 5q33.2, a chromosomal region that has been repeatedly associated with asthma, allergy and autoimmunity (4).

Tim-3 was found to be particularly expressed in T helper type 1 (Th1) cells, CD8+ T cells and Th17 cells. At present, Tim-3 expression may be found in innate immune cells, including natural killer (NK) cells, dendritic cells (DCs), monocytes, mast cells and other lymphocyte subpopulations (5–8).

In recent years, Tim-3 has been considered to be a negative regulatory molecule, which plays a crucial role in antitumor immunity. However, the mechanism underlying its antitumor properties remains unknown. The aim of this study was to investigate the expression of Tim-3 in 150 invasive ductal breast cancer (IDC) and 100 normal breast tissue samples by immunohistochemistry and determine the expression of Tim-3 in breast cancer tissue and its association with clinicopathological parameters and cytotoxic lymphocyte (CTL) infiltration.

 Patients and methods <sec> <title>Patient selection

A total of 150 breast cancer tissue specimens were collected from female patients at the Department of Breast Surgery of the Southwest Medical University Affiliated Hospital (Sichuan, China) between April, 2013 and May, 2014; all the cases were pathologically diagnosed postoperatively. Following selection of the paraffin blocks, 4-µm sections were prepared, stained with hematoxylin and eosin (HE), and the diagnosis was confirmed by two pathologists. Sections with inflammation, hemorrhage and incisional biopsies with insufficient tissue were excluded from the study. Clinical information, including age, primary tumor size, axillary lymph node metastasis and TNM stage, World Health Organization (WHO) grade, Ki-67, molecular classification and location of the lesion, was extracted from patient files and recorded in tables. The median age of the patients was 49.6 years (range, 33–68 years). Patients without any complications did not receive chemotherapy or other therapies prior to surgery. Furthermore, 100 pathologically confirmed normal breast tissue or benign lesion samples were also obtained, located at a distance 3.0–5.0 cm from the tumor. All the participants provided written informed consent and the study protocol was approved by the Ethics Committee of the Affiliated Hospital of Xinan Medical University. The study was conducted over a period of 6 months.

 Reagents and instruments

Rabbit anti-human Tim-3 polyclonal antibody (dilution, 1:500; catalog no., 185703; Abcam, Cambridge, UK); murine monoclonal anti-human CD8 antibody (dilution 1:500, GM710301, Gene Biology Company, Shanghai, China), 10% neutral buffered formalin, xylene, serial concentrations of ethanol, phosphate-buffered solution (PBS), 3% H2O2 and diaminobenzidine (DAB) (all from Jinshan Chemical Reagent Company, Chengdu, China).

 Immunohistochemistry

To quantify Tim-3 cells in large numbers of patients, paraffin-embedded IDC samples were processed for immunohistochemistry. The specimens were fixed in 10% neutral buffered formalin, embedded in paraffin and cut into 4-µm serial sections. Paraffin-embedded tissues were dewaxed in xylene, rehydrated by serial concentrations of ethanol and rinsed in PBS, followed by treatment with 3% H2O2 to block endogenous peroxidase. Following heating in a microwave at 750 W for 15 min to retrieve the tissue antigen, the sections were incubated with 10% normal goat serum at room temperature for 10 min to block non-specific reactions. This was followed by washing with PBS and incubation with polyclonal rabbit anti-human Tim-3 antibody (dilution, 1:500, clone 185703, IgG2a; Abcam), murine monoclonal anti-human CD8 antibody, for 12 h at 4°C, and with horseradish peroxidase-conjugated goat anti-rat IgG (dilution, 1:500; GM710301; Gene Biology Company, Shanghai, China). Following washing with PBS, the sections were developed in DAB substrate. The sections were then counterstained with hematoxylin for 2 min and dehydrated in ethanol and xylene prior to mounting on slides. The sections were subjected to EnVision immunohistochemical staining. PBS instead of primary antibodies was used as negative control. Visualization was achieved with ABC-Elite Reagent (Sigma, St. Louis, MO, USA). The sections were counterstained with Mayer's hematoxylin (Sigma). The nuclei were stained with 1% ammonium hydroxide. The number of Tim-3 cells was counted in five fields at a magnification of ×400.

 Statistical analysis

All the data were analyzed with the SPSS software package, version 17.0 (SPSS Inc., Chicago, IL, USA). Due to the non-normal distribution, the Mann-Whitney U-test was used for comparison between groups. Independent samples t-test was used for the comparison of two means; the Chi-squared test was used for rate comparison. P-values <0.05 were considered to indicate statistically significant differences.

 Results <sec> <title>Expression of Tim-3 in the tissue of invasive breast carcinoma and normal breast tissue

Tim-3 was found to be expressed on the surface of the tumor cells (Fig. 1) and CD8+ T cells (Fig. 2). Tim-3 expression on IDC cells (98%) was significantly higher compared with that in normal breast tissue (13%; χ2=0.195, P=0.000). Similarly, the expression of Tim-3 on CD8+ T cells in IDC tissue (90%) was also significantly increased compared with that in normal breast tissue (23%; χ2=11.11, P=0.000; Table I).

 Association between Tim-3 expression and clinicopathological characteristics in IDC patients

The expression of Tim-3 on tumor cells was significantly associated with clinicopathological characteristics, such as gender, age, lymph node metastasis and TNM stage (P=0.015, 0.001 and 0.027, respectively). Our study indicated that the median expression level of Tim-3 on CD8+ T cells was significantly associated with clinicopathological parameters such as lymph node metastasis, TNM stage, WHO grade and molecular classification (P=0.000, 0.004, 0.009 and 0.000, respectively), whereas it was not correlated with other clinicopathological parameters (all P-values >0.05; Table II).

 Association between Tim-3 expression and the degree of CD<sup>+</sup>8 T-cell infiltration

The degree of CD8+ T-cell infiltration in IDC (Fig. 3) was higher compared with that in normal breast tissue (Fig. 4). Further analysis revealed that the degree of CD8+ T-cell infiltration was significantly correlated with primary tumor size, lymph node metastasis, WHO grade, Ki-67 and molecular classification (P=0.017, 0.002, 0.007, 0.003 and 0.000, respectively), whereas it was not correlated with other clinicopathological parameters (all P-values >0.05; Table III).

Furthermore, by evaluating the abovementioned parameters that were statistically significant by logistic multifactor regression analysis, axillary lymph node metastasis, WHO grade, Ki-67 and molecular classification were found to significantly affect the extent of the tumor infiltration by CTLs (all P-values <0.05; Table IV).

 Discussion

Co-opted immune checkpoint pathways are likely involved in the mechanism underlying tumor immune suppression. Tim-3 is a newly confirmed molecule with an important immunological function in several physiological and pathological processes.

Tim-3 was initially found to be selectively expressed on terminally differentiated interferon γ-producing CD4+ Th1 cells and CD8+ cytotoxic T cells (9,10), as well as on Th17 cells, DCs, monocytes, regulatory T cells (Tregs), mast cells, NK cells and tumor-infiltrating lymphocytes. It is also expressed on tumor cells, such as melanoma, squamous cell carcinoma, gastric cancer and non-small-cell lung cancer cells, but not on CD4+ Th2 cells (10–18).

Previous studies suggested that Tim-3 may modulate the immune response of Th1 cells and regulate cell immune tolerance (19,20). Tim-3 has also drawn significant attention in autoimmune diseases, anaphylactic diseases, immune tolerance and antitumor immunity (21,22). The Tim-3/galectin-9 pathway plays an important role in the suppressive tumor microenvironment (TME). In a variety of cancers, the overexpression of Tim-3 is associated with poor prognosis (9).

Tim-3 marks the most suppressed or dysfunctional population of CD8+ T cells in preclinical models of solid as well as hematological malignancies; thus, Tim-3 may be a key immune checkpoint in tumor-induced immune suppression (18,23).

The Tim-3/galectin-9 pathway contributes to the TME in the human body and Tim-3 is also characterized as a key regulator of the dysfunctional CD8+ T-cell phenotype (18,24) early in the TME, where neoplastic growth is promoted via induction of CD8+ T-cell dysfunctionality (25).

Several recent studies demonstrated that Tim-3 is highly expressed in a large number of tumor tissues types, including cervical cancer (15), gastric cancer (16), acute myeloid leukemia (23) lung cancer (25), ovarian cancer (26) and glioma (27). In this study, the Tim-3 expression on tumor cells and CD8+ T cells of IDC and normal breast tissues was investigated by immunohistochemistry. The expression of Tim-3 in IDC tissue was distinctly higher compared with that in normal breast tissue (P=0.000), which suggested that Tim-3 was involved in the pathogenesis of breast cancer via its regulatory effect on various immune cells and tumor cells, indicating that Tim-3 may play an important role in tumorigenesis. The expression of Tim-3 on tumor cells may affect the malignant biological behavior of the tumor.

In the present study, we observed that the expression of Tim-3 in IDC was significantly associated with age (P<0.05), reflecting the decrease in the overall immune ability of the body with advancing age. The expression of the negative regulatory immune molecule Tim-3 on breast cancer cells was clearly increased.

Our test results also demonstrated that the strength of the Tim-3 expression on tumor cells exhibited an increasing trend with the increasing number of metastatic axillary lymph nodes and advanced pathological stage. Furthermore, the expression of Tim-3 on IDC cells was significantly correlated with local axillary lymph node metastasis and pathological stage (P<0.05), but the results of our study demonstrated that primary tumor size, WHO grade, Ki-67 and molecular classification of breast IDC were not significantly associated with the expression of Tim-3 on tumor cells. The possible underlying mechanisms may be as follows: i) A large amount of Tim-3 on the tumor cell surface forms a ‘shield’ to protect Tim-3-positive tumor cells from the toxicity of immunological effector cells; however, the expression of negative immune regulatory factor Tim-3 does not affect the proliferation and differentiation of tumor cells. ii) In some cases, the size of the primary tumor is large at clinical diagnosis; thus, immune adjustment factors are no longer able to interfere with the growth of tumor cells, or there is a disproportional rate of tumor cell proliferation and immune clearance. iii) The experimental data may be insufficient; thus, larger samples are required to confirm the findings.

In nearly all previous studies, immune cells were identified by specific cluster of differentiation (CD) markers, following immunohistochemical staining of the slides. It is important to distinguish between different types of T lymphocytes, as they all have different functions in the TME.

CD8+ T cells play an important role in the TME. CTL is the main antitumor immune cell type, which may identify tumor antigens and eliminate tumor cells with one of two main mechanisms: i) The perforin pathway, or ii) the Fas/FasL-mediated apoptosis pathway. Fourcade et al (28) discovered that Tim-3 was expressed on NY-ESO-1-specific CD8+ T cells in patients with advanced melanoma. They found that the blockade of both the Tim-3 and programmed cell death protein-1 (PD-1) pathways may reverse tumor-induced T-cell exhaustion in patients with advanced melanoma. Our results suggested that the Tim-3 expression on CD8+ T cells was correlated with tumor invasion and TNM stage, which may be due to Tim-3-induced T-cell exhaustion, leading to tumor occurrence.

Our test data demonstrated that the expression of Tim-3 on tumor-infiltrating CTLs increased as axillary lymph node metastasis progressed. Lymph node metastasis and TNM stage, primary tumor size, WHO grade and molecular classification are significantly associated with the expression of Tim-3 on CTL cells (P<0.05).

This indicates that the expression of Tim-3 on CTLs may inhibit the tumor cell-killing function of CTLs. Even in the TME, CD8+ CTLs may transform into CD8+ Tregs, decreasing the tumor-infiltrating CTL immune surveillance, decreasing the local immune function and promoting the growth of tumor cells and metastasis.

The present study analyzed the association of tumor-infiltrating CTLs and the pathological characteristics of breast-infiltrating ductal carcinoma by single factor analysis of variance and demonstrated that primary tumor size, axillary lymph node metastasis, WHO grade, Ki-67 and molecular classification may statistically significantly affect the degree of tumor CTL infiltration (P<0.05).

Furthermore, the abovementioned statistically significant parameters were assessed by multiple logistic regression analysis and the results also demonstrated that axillary lymph node metastasis, WHO grade, Ki-67 and molecular classification significantly affect the extent of CTL infiltration of the tumor. The possible underlying mechanism may be as follows: i) High expression of the negative immunomodulatory molecule Tim-3 on tumor-infiltrating CTLs may result in immune malfunction; as the tumor grows, CD8+ CTLs may transform into CD8+ Tregs. ii) Low degree of CTL infiltration may lead to poor local immunity, which may contribute to tumor growth. iii) The lower the degree of tumor differentiation, the higher its antigenicity, which may cause a stronger local immune response.

In conclusion, Tim-3 is expressed in the majority of solid tumors and tumor-infiltrating CTLs. This finding suggests that Tim-3 participates in the immune escape through the following mechanisms: i) When it binds to its receptor, Tim-3 may induce T-cell apoptosis or immune incompetence; ii) a large amount of Tim-3 on the tumor cell surface may form a ‘shield’, which may protect Tim-3-positive tumor cells from toxic injury or elimination by CTLs; iii) Tim-3 positive cells may also affect T-cell secretion of negative cytokines or Treg coordination.

Sakuishi et al (18) reported that, in lymphocytes infiltrating solid tumors in mice, co-expression of Tim-3 and PD-1 may be detected. The multi-targeted therapy of Tim-3 and PD-1 has been highly effective in controlling tumor growth. Our study demonstrated that the expression of Tim-3 in breast cancer tissue was negatively correlated with certain clinicopathological parameters; however, the underlying mechanisms remain unclear. Therefore, further research on the multi-targeted therapy of Tim-3 and PD-1 for the treatment of breast cancer.

In conclusion, Tim-3 is highly expressed in breast IDC cells and tumo-infiltrating CTLs. The expression of Tim-3 exhibits a positive correlation with the malignant behavior of the tumor. The expression of Tim-3 on CTLs is negatively correlated with degree of CTL infiltration, and Tim-3 expression in breast cancer exerts a negative effect on immune regulation. The largest diameter of the primary tumor, the number of metastatic axillary lymph nodes, degree of tumor cell differentiation and molecular classification of breast cancer significantly afect the extent of the CTL infiltration of the tumor tissue.

 References FerlayJShinHRBrayFFormanDMathersCParkinDMEstimates of worldwide burden of cancer in 2008: GLOBOCAN 2008Int J Cancer12728932917201010.1002/ijc.2551621351269 EcclesSAAboagyeEOAliSAndersonASArmesJBerditchevskiFBlaydesJPBrennanKBrownNJBryantHECritical research gaps and translational priorities for the successful prevention and treatment of breast cancerBreast Cancer Res15R92201310.1186/bcr349324286369 McIntireJJUmetsuSEAkbariOPotterMKuchrooVKBarshGSFreemanGJUmetsuDTDeKruyffRHIdentification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene familyNat Immunol211091116200110.1038/ni73911725301 McIntireJJUmetsuDTDeKruyffRHTIM-1, a novel allergy and asthma susceptibility geneSpringer Semin Immunopathol25335348200410.1007/s00281-003-0141-315007635 HastingsWDAndersonDEKassamNKoguchiKGreenfieldEAKentSCZhengXXStromTBHaflerDAKuchrooVKTIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokinesEur J Immunol3924922501200910.1002/eji.20093927419676072 AndersonACAndersonDEBregoliLHastingsWDKassamNLeiCChandwaskarRKarmanJSuEWHirashimaMPromotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cellsScience31811411143200710.1126/science.114853618006747 KhademiMIllésZGielenAWMartaMTakazawaNBaecher-AllanCBrundinLHannerzJMartinCHarrisRAT Cell Ig- and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosisJ Immunol17271697176200410.4049/jimmunol.172.11.716915153541 NakaeSIikuraMSutoHAkibaHUmetsuDTDekruyffRHSaitoHGalliSJTIM-1 and TIM-3 enhancement of Th2 cytokine production by mast cellsBlood11025652568200710.1182/blood-2006-11-05880017620455 AndersonACTim-3, a negative regulator of anti-tumor immunityCurr Opin Immunol24213216201210.1016/j.coi.2011.12.00522226204 AndersonACAndersonDEBregoliLHastingsWDKassamNLeiCChandwaskarRKarmanJSuEWHirashimaMPromotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cellsScience31811411143200710.1126/science.114853618006747 NgiowSFTengMWSmythMJProspects for TIM3-targeted antitumor immunotherapyCancer Res7165676571201110.1158/0008-5472.CAN-11-148722009533 WienerZKohalmiBPoczaPJeagerJTolgyesiGTothSGorbeEPappZFalusATIM-3 is expressed in melanoma cells and is upregulated in TGF-beta stimulated mast cellsJ Invest Dermatol127906914200710.1038/sj.jid.570061617096021 ZhuangXZhangXXiaXZhangCLiangXGaoLZhangXMaCEctopic expression of TIM-3 in lung cancers: A potential independent prognostic factor for patients with NSCLCAm J Clin Pathol137978985201210.1309/AJCP9Q6OVLVSHTMY22586058 YanJZhangYZhangJPLiangJLiLZhengLTim-3 expression defines regulatory T cells in human tumorsPLoS One8e58006201310.1371/journal.pone.005800623526963 CaoYZhouXHuangXLiQGaoLJiangLHuangMZhouJTim-3 expression in cervical cancer promotes tumor metastasisPLoS One8e53834201310.1371/journal.pone.005383423335978 JiangJJinMSKongFCaoDMaHXJiaZWangYPSuoJCaoXDecreased galectin-9 and increased Tim-3 expression are related to poor prognosis in gastric cancerPLoS One8e81799201310.1371/journal.pone.008179924339967 YangZZGroteDMZiesmerSCNikiTHirashimaMNovakAJWitzigTEAnsellSMIL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphomaJ Clin Invest12212711282201210.1172/JCI5980622426209 SakuishiKApetohLSullivanJMBlazarBRKuchrooVKAndersonACTargeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunityJ Exp Med20721872194201010.1084/jem.2010064320819927 Sánchez-FueyoATianJPicarellaDDomenigCZhengXXSabatosCAManlongatNBenderOKamradtTKuchrooVKTim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological toleranceNat Immunol410931101200310.1038/ni98714556005 SabatosCAChakravartiSChaESchubartASánchez-FueyoAZhengXXCoyleAJStromTBFreemanGJKuchrooVKInteraction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral toleranceNat Immunol411021110200310.1038/ni98814556006 SimmonsWJKoneruMMohindruMThomasRCutroSSinghPDekruyffRHInghiramiGCoyleAJKimBSPonzioNMTim-3+ T-bet+ tumor-specific Th1 cells colocalize with and inhibit development and growth of murine neoplasmsJ Immunol17414051415200510.4049/jimmunol.174.3.140515661898 HuWKLuXXYangSXuGPLanFChenSXNiWXiongWNXiongSDExpression of the Th1-specific cell-surface protein Tim-3 increases in a murine model of atopic asthmaJ Asthma46872877200910.3109/0277090090319995319905911 ZhouQMungerMEVeenstraRGWeigelBJHirashimaMMunnDHMurphyWJAzumaMAndersonACKuchrooVKBlazarBRCoexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemiaBlood11745014510201110.1182/blood-2010-10-31042521385853 TakamuraSTsuji-KawaharaSYagitaHAkibaHSakamotoMChikaishiTKatoMMiyazawaMPremature terminal exhaustion of Friend virus-specific effector CD8+ T cells by rapid induction of multiple inhibitory receptorsJ Immunol18446964707201010.4049/jimmunol.090347820351188 GaoXZhuYLiGHuangHZhangGWangFSunJYangQZhangXLuBTIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progressionPLoS One7e30676201210.1371/journal.pone.003067622363469 WuJLiuCQianSHouHThe expression of Tim-3 in peripheral blood of ovarian cancerDNA Cell Biol32648653201310.1089/dna.2013.211624007284 HanSFengSXuLShiWWangXWangHYuCDongTXuMLiangGTim-3 on peripheral CD4+ and CD8+ T cells is involved in the development of gliomaDNA Cell Biol33245250201410.1089/dna.2013.230624512143 FourcadeJSunZBenallaouaMGuillaumePLuescherIFSanderCKirkwoodJMKuchrooVZarourHMUpregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+T cell dysfunction in melanoma patientsJ Exp Med20721752186201010.1084/jem.2010063720819923

Photomicrograph showing high expression of Tim-3 on invasive ductal breast carcinoma cells (immunohistochemical staining; original magnification, ×400). Tim-3, T-cell immunoglobulin and mucin domain-3.

Photomicrograph of a section showing high expression of Tim-3 on the cytotoxic lymphocytes infiltrating invasive ductal breast carcinoma (immunohistochemical staining; original magnification, ×400). Tim-3, T-cell immunoglobulin and mucin domain-3.

Photomicrograph of a section showing the extensive infiltration by CD8+ T-cells in invasive ductal breast carcinoma tissue (immunohistochemical staining; original magnification, ×200).

Photomicrograph of a section showing limited infiltration by CD8+ T-cells in normal breast tissue (immunohistochemical staining; original magnification, ×200).

Expression of Tim-3 on breast tissue cells and on CTLs in IDC and normal breast or benign lesions.

Expression of Tim-3 on breast tissue cells Expression of Tim-3 on CTLs
Variables Patient no. High (n) Rate (%) High (n) Rate (%)
IDC 150 147 98 135 90
Normal breast/benign lesions 100   13 13 23 23
χ2 0.195 11.11
P-value 0.000 0.000

Tim-3, T-cell immunoglobulin and mucin domain-3; CTL, cytotoxic lymphocyte; IDC, invasive ductal carcinoma.

Association between the expression of Tim-3 and the clinicopathological characteristics of patients with breastinfiltrating ductal carcinoma.

Tim-3 expression
On tumor cells On CTLs
Variables Patient no. (n=150) Low (%) High (%) P-value Low (%) High (%) P-value
Age, years 0.015 0.991
  <45 48 27 (56.25) 21 (43.75) 24 (50.00) 24 (50.00)
  ≥45 102 36 (35.29) 66 (64.71) 52 (50.98) 50 (49.02)
Tumor size 0.422 0.114
  T1 51 24 (47.06) 27 (52.94) 31 (60.78) 20 (39.21)
  T2 36 15 (41.67) 21 (58.33) 18 (50.00) 18 (50.00)
  T3 60 24 (40.00) 36 (60.00) 27 (45.00) 33 (55.00)
  T4 3   0 (0.00)   3 (100.00)   0 (0.00)   3 (100.00)
Lymph node status 0.001 0.000
  N0 42 21 (50.00) 21 (50.00) 36 (85.71)   6 (14.29)
  N1 69 36 (52.17) 33 (47.82) 28 (40.58) 41 (59.42)
  N2 24   3 (12.50) 21 (87.50)   6 (25.00) 18 (75.00)
  N3 15   3 (20.00) 12 (80.00)   6 (40.00)   9 (60.00)
TNM stage 0.027 0.004
  I 18 12 (66.67)   6 (33.33) 10 (55.56)   8 (44.44)
  II 42 21 (50.00) 21 (50.00) 30 (71.43) 12 (28.57)
  III 60 18 (30.00) 42 (70.00) 27 (45.00) 33 (55.00)
  IV 30 12 (40.00) 18 (60.00)   9 (30.00) 21 (70.00)
WHO grade 0.536 0.009
  I 15   6 (40.00)   9 (50.00)   3 (20.00) 12 (80.00)
  II 99 39 (39.39) 60 (60.61) 49 (49.49) 50 (50.51)
  III 36 18 (50.00) 18 (50.00) 24 (66.67) 12 (33.33)
Ki-67, % 0.630 0.512
  <14 39 15 (38.46) 24 (61.24) 18 (46.15) 21 (53.85)
  ≥14 111 48 (43.24) 63 (56.76) 58 (52.25) 53 (47.75)
Molecular classification 0.314 0.000
  Luminal A 24   9 (37.50) 15 (62.50) 15 (62.50)   9 (37.50)
  Luminal B 60 30 (50.00) 30 (50.00) 18 (30.00) 42 (60.00)
  HER2-overexpressing 36 15 (41.67) 21 (58.33) 19 (52.78) 17 (47.22)
  Basal-like 30   9 (30.00) 21 (70.00) 24 (80.00)   6 (20.00)

Tim-3, T-cell immunoglobulin and mucin domain-3; CTL, cytotoxic lymphocyte; TNM, tumor-node-metastasis; WHO, World Health Organization; HER2, human epidermal growth factor receptor 2.

Association between expression of Tim-3 on CTLs and the clinicopathological parameters of breast infiltrating ductal carcinoma.

Expression of Tim-3 on CTLs
Variables Patient no. (n=150) Low (%) High (%) χ2 P-value
Age, years 3.160 0.075
  <45 48 18 (37.50) 30 (62.50)
  ≥45 102 24 (23.53) 78 (76.47)
Tumor size 10.177 0.017
  T1 51 15 (29.41) 36 (70.59)
  T2 36   6 (16.67) 30 (83.33)
  T3 60 18 (30.00) 42 (70.00)
  T4 3   3 (100.00)   0 (0.00)
Lymph node status 14.482 0.002
  N0 42   3 (7.14) 39 (92.87)
  N1 69 27 (39.13) 42 (60.87)
  N2 24   6 (25.00) 18 (75.00)
  N3 15   6 (40.00)   9 (60.00)
TNM stage 3.564 0.313
  I 18   3 (16.67) 15 (83.33)
  II 42 12 (28.57) 30 (71.43)
  III 60 15 (25.00) 45 (75.00)
  IV 30 12 (40.00) 18 (60.00)
WHO grade 9.939 0.007
  I 15   9 (60.00)   6 (40.00)
  II 99 27 (27.27) 72 (72.72)
  III 36   6 (16.67) 30 (83.33)
Ki-67 8.615 0.003
  <14% 39 18 (46.15) 21 (53.85)
  ≥14% 111 24 (21.62) 87 (78.38)
Molecular classification 23.636 0.000
  Luminal A 24   9 (37.50) 15 (62.50)
  Luminal B 60 27 (45.00) 33 (55.00)
  HER2-overexpressing 36   6 (16.67) 30 (83.33)
  Basal-like 30   0 (0.00) 30 100.00)
Tim-3 expression on tumor 0.946 0.331
  Low 63 15 (23.80) 48 (76.20)
  High 87 27 (31.03) 60 (68.97)

CTL, cytotoxic lymphocyte; TNM, tumor-node-metastasis; WHO, World Health Organization; HER2, human epidermal growth factor receptor 2; Tim-3, T-cell immunoglobulin and mucin domain-3.

Analysis of multiple factors affecting the infiltration degree by CTLs.

Exp(B) CI 95%
Variables B SE Wald df Sig Exp(B) Upper limit Lower limit
Tumor size −13.962   0.685 425.901 1   0.229   1.767   0.488   8.566
Lymph node status −4.649   1.387 11.236 1   0.001   0.010   0.046   1.345
WHO grade   0.576   1.137 .257 1   0.002   1.779   0.023   0.665
Ki-67   1.240   0.860 39.34 1   0.038   3.456   1.020 29.720
Molecular classification 16.910 985.39   0.000 1   0.000   2.200E9   7.140E8   4.791E10
Tim-3 expression on tumor −0.983   0.640   2.359 1   0.125   0.374   1.07   1.312

CTLs, cytotoxic lymphocytes; WHO, World Health Organization; SE, standard error; df, degree of freedom; CI, confidence interval.